RxDoctor Payments Data

Cary Caldwell, MD

Gastroenterology · New Haven, CTNPI 1194866038

Payments from drug & device makers

$5,514in general payments, 2019–2025

Across 317 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Gilead$973
  • Takeda Pharmaceuticals U.S.A., Inc.$807
  • Johnson & Johnson$370
  • Bristol Myers Squibb$213
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,491100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,514 in reported general payments places this provider in the 60th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$76,334
Medicare patients
214
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin101$341,348
Ursodiol165$33,302
VemlidyTenofovir Alafenamide20$28,004
Envarsus XrTacrolimus26$24,787
LokelmaSodium Zirconium Cyclosilicate21$15,664
Tacrolimus149$14,641
Mesalamine ErMesalamine17$9,974
Ondansetron Hcl27$8,334
Mycophenolate Mofetil57$7,277
Sirolimus16$5,947
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates72$4,292
Pantoprazole Sodium341$3,336
Lactulose62$2,567
Omeprazole137$2,439
Lubiprostone12$1,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,072$341,348101 claims
GileadVemlidy$973$28,00420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →